Patient initiation and maintenance of GLP-1 RAs for treatment of obesity
Open accessThe DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
Introduction: Healthcare providers (HCPs) see many patients with obesity-related complications and are therefore well placed to help treat obesity itself. However, limited collated information exists to help HCPs with the practical use of anti-obesity medications (AOMs). We focus on the initiation and maintenance of a glucagon-like peptide-1 receptor agonist (GLP-1 RA) for weight management, liraglutide 3.0 mg. Literature search was conducted between 25–28 November 2019 on PubMed and ClinicalTrials.gov.Areas covered: Clinical trial and real-world data describing weight-loss efficacy, cardiometabolic risk factors, incidence of adverse events (AEs), and persistence are presented to assist HCPs with patient discussions. Practical considerations to overcome barriers to optimal use are provided, equipping HCPs with the information required to aid with adherence to and persistence with AOMs. The use of other GLP-1- RA therapies in obesity is discussed in light of the recent US Food and Drug Administration approval of semaglutide 2.4 mg for weight management.Expert opinion: Liraglutide 3.0 mg provides benefits regarding weight loss and improvements in cardiometabolic risk factors. Promising areas of future research in the field of obesity include dual receptor agonists and the combination of glucagon-like peptide-1 receptor agonists with other molecules.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Guh, D. P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C. L., & Anis, A. H. (2009) · BMC Public Health · doi:10.1186/1471-2458-9-88 · Cited by 3,855
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Bray, G. A., Kim, K. K., Wilding, J. P. H., & on behalf of the World Obesity Federation (2017) · Obesity Reviews · doi:10.1111/obr.12551 · Cited by 1,612
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114
González-Muniesa, P., Mártinez-González, M.-A., Hu, F. B., Després, J.-P., Matsuzawa, Y., Loos, R. J. F., Moreno, L. A., Bray, G. A., & Martinez, J. A. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.34 · Cited by 1,113
Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876
le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850
on behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
Frias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
O'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. H. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31773-2 · Cited by 814
Mojsov, S., Heinrich, G., Wilson, I. B., Ravazzola, M., Orci, L., & Habener, J. F. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67324-7 · Cited by 724
A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
Kelly, A. S., Auerbach, P., Barrientos-Perez, M., Gies, I., Hale, P. M., Marcus, C., Mastrandrea, L. D., Prabhu, N., & Arslanian, S. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916038 · Cited by 723
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12932 · Cited by 693
Nauck, M. A., Heimesaat, M. M., Behle, K., Holst, J. J., Nauck, M. S., Ritzel, R., Hüfner, M., & Schmiegel, W. H. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8355 · Cited by 605
on behalf of the SCALE study group, Blackman, A., Foster, G. D., Zammit, G., Rosenberg, R., Aronne, L., Wadden, T., Claudius, B., Jensen, C. B., & Mignot, E. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.52 · Cited by 583
Metabolic and hedonic drives in the neural control of appetite: who is the boss?
Berthoud, H.-R. (2011) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2011.09.004 · Cited by 499
Capehorn, M. S., Catarig, A.-M., Furberg, J. K., Janez, A., Price, H. C., Tadayon, S., Vergès, B., & Marre, M. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.101117 · Cited by 412
Thomas, M. K., Nikooienejad, A., Bray, R., Cui, X., Wilson, J., Duffin, K., Milicevic, Z., Haupt, A., & Robins, D. A. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa863 · Cited by 345
Perceptions of Barriers to Effective Obesity Care: Results from the National ACTION Study
Kaplan, L. M., Golden, A., Jinnett, K., Kolotkin, R. L., Kyle, T. K., Look, M., Nadglowski, J., O'Neil, P. M., Parry, T., Tomaszewski, K. J., et al. (2018) · Obesity · doi:10.1002/oby.22054 · Cited by 312
Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
Madsbad, S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12596 · Cited by 305
Determinants of weight loss maintenance: a systematic review
Varkevisser, R. D. M., van Stralen, M. M., Kroeze, W., Ket, J. C. F., & Steenhuis, I. H. M. (2019) · Obesity Reviews · doi:10.1111/obr.12772 · Cited by 295
Church, T. S., Kuk, J. L., Ross, R., Priest, E. L., Biltoff, E., & Blair, S. N. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.03.019 · Cited by 268
Caterson, I. D., Hubbard, V., Bray, G. A., Grunstein, R., Hansen, B. C., Hong, Y., Labarthe, D., Seidell, J. C., & Smith, S. C. (2004) · Circulation · doi:10.1161/01.cir.0000140114.83145.59 · Cited by 264
The Role of GLP-1 in the Metabolic Success of Bariatric Surgery
Hutch, C. R., & Sandoval, D. (2017) · Endocrinology · doi:10.1210/en.2017-00564 · Cited by 236
Obesity as a risk factor for Alzheimer's disease: weighing the evidence
Alford, S., Patel, D., Perakakis, N., & Mantzoros, C. S. (2018) · Obesity Reviews · doi:10.1111/obr.12629 · Cited by 217
Self-citationThe obesity pipeline: current strategies in the development of anti-obesity drugs
Cooke, D., & Bloom, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2136 · Cited by 211
Sleep Apnea and Cardiovascular Disease: An Enigmatic Risk Factor
Floras, J. S. (2018) · Circulation Research · doi:10.1161/circresaha.118.310783 · Cited by 209
Wadden, T. A., Tronieri, J. S., Sugimoto, D., Lund, M. T., Auerbach, P., Jensen, C., & Rubino, D. (2020) · Obesity · doi:10.1002/oby.22726 · Cited by 200
Garvey, W. T., Birkenfeld, A. L., Dicker, D., Mingrone, G., Pedersen, S. D., Satylganova, A., Skovgaard, D., Sugimoto, D., Jensen, C., & Mosenzon, O. (2020) · Diabetes Care · doi:10.2337/dc19-1745 · Cited by 186
Breaking Down Patient and Physician Barriers to Optimize Glycemic Control in Type 2 Diabetes
Ross, S. A. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.06.012 · Cited by 172
Reasons for underutilization of bariatric surgery: The role of insurance benefit design
Gasoyan, H., Tajeu, G., Halpern, M. T., & Sarwer, D. B. (2019) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2018.10.005 · Cited by 171
Li, C., Ford, E. S., Zhao, G., Croft, J. B., Balluz, L. S., & Mokdad, A. H. (2010) · Preventive Medicine · doi:10.1016/j.ypmed.2010.03.016 · Cited by 157
Safety and tolerability of new-generation anti-obesity medications: a narrative review
Patel, D. K., & Stanford, F. C. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1435129 · Cited by 131
Self-citationPharmacotherapy for the management of obesity
Patel, D. K. (2015) · Metabolism · doi:10.1016/j.metabol.2015.08.001 · Cited by 128
Self-citationWadden, T. A., Walsh, O. A., Berkowitz, R. I., Chao, A. M., Alamuddin, N., Gruber, K., Leonard, S., Mugler, K., Bakizada, Z., & Tronieri, J. S. (2019) · Obesity · doi:10.1002/oby.22359 · Cited by 116
Davies, M. J., Aronne, L. J., Caterson, I. D., Thomsen, A. B., Jacobsen, P. B., Marso, S. P., & groups, O. B. O. T. S. A. C. A. –. L. E. I. I. W. A. W. D. (. S. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13125 · Cited by 115
Bariatric surgery barriers: a review using Andersen’s Model of Health Services Use
Imbus, J. R., Voils, C. I., & Funk, L. M. (2017) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2017.11.012 · Cited by 100
Nauck, M. A., Jensen, T. J., Rosenkilde, C., Calanna, S., Buse, J. B., & the LEADER Publication Committee on behalf of the LEADER Trial Investigators (2018) · Diabetes Care · doi:10.2337/dc17-1825 · Cited by 94
Krieger, J.-P. (2020) · Peptides · doi:10.1016/j.peptides.2020.170342 · Cited by 91
Dynamic Interplay Among Homeostatic, Hedonic, and Cognitive Feedback Circuits Regulating Body Weight
Hall, K. D., Hammond, R. A., & Rahmandad, H. (2014) · American Journal of Public Health · doi:10.2105/ajph.2014.301931 · Cited by 80
Real‐World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada
Wharton, S., Liu, A., Pakseresht, A., Nørtoft, E., Haase, C. L., Mancini, J., Power, G. S., Vanderlelie, S., & Christensen, R. A. G. (2019) · Obesity · doi:10.1002/oby.22462 · Cited by 77
Apovian, C. M., Garvey, W. T., & Ryan, D. H. (2015) · Obesity · doi:10.1002/oby.21140 · Cited by 72
Bariatric surgery insurance requirements independently predict surgery dropout
Love, K. M., Mehaffey, J. H., Safavian, D., Schirmer, B. D., Malin, S. K., Hallowell, P. T., & Kirby, J. L. (2017) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2017.01.022 · Cited by 69
A randomized, controlled trial of liraglutide for adolescents with obesity
Kelly, A. S., Auerbach, P., Pérez, M. B., Gies, I., Pm, H., Marcus, C., Mastrandrea, L. D., & Prabhu, N. (2020) · Yearbook of pediatric endocrinology · doi:10.1530/ey.17.11.12 · Cited by 67
M, M, M & M: a mnemonic for assessing obesity
Sharma, A. M. (2010) · Obesity Reviews · doi:10.1111/j.1467-789x.2010.00766.x · Cited by 60
Hypothalamic regulation of appetite
Simpson, K. A., Martin, N. M., & Bloom, S. R. (2008) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.3.5.577 · Cited by 56
Combined Amylin/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss
Liberini, C. G., Koch-Laskowski, K., Shaulson, E., McGrath, L. E., Lipsky, R. K., Lhamo, R., Ghidewon, M., Ling, T., Stein, L. M., & Hayes, M. R. (2019) · Scientific Reports · doi:10.1038/s41598-019-44591-8 · Cited by 50
Del Prato, S., Kang, J., Trautmann, M. E., Stewart, J., Sorli, C. H., Derwahl, M., Soto, A., & Yoon, K. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14020 · Cited by 43
Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
Unger, J. R., & Parkin, C. G. (2011) · Diabetes Therapy · doi:10.1007/s13300-010-0013-5 · Cited by 38
Wharton, S., Haase, C. L., Kamran, E., Liu, A., Mancini, J., Neish, D., Pakseresht, A., Power, G. S., & Christensen, R. A. G. (2020) · Obesity Science & Practice · doi:10.1002/osp4.420 · Cited by 26
Tronieri, J. S., Wadden, T. A., Walsh, O., Berkowitz, R. I., Alamuddin, N., & Chao, A. M. (2020) · Behaviour Research and Therapy · doi:10.1016/j.brat.2020.103639 · Cited by 21
GLP-1 Based Combination Therapy for Obesity and Diabetes
Lee, Y. H., Lee, H. W., & Choi, H. J. (2017) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes.2017.26.3.155 · Cited by 12
Liraglutide pancreatitis: The ABCD nationwide liraglutide audit
Ryder, R. E. J., Thong, K. Y., Blann, A. D., Phillips, S., Barwell, N., Kelly, C., Semple, C., CULL, M. L., Gupta, P. S., & contributors, F. T. A. N. L. A. (2013) · The British Journal of Diabetes · doi:10.1177/1474651413502685 · Cited by 11
Haider, A., Dhindsa, G., & Burks, J. (2016) · Endocrine Practice · doi:10.1016/s1530-891x(20)44912-2 · Cited by 2
Merchenthaler (1999) · doi:10.1002/(sici)1096-9861(19990111)403:2<261::aid-cne8>3.0.co;2-5
Research works printed but not linked: 6
- Garvey WT, 2016, Endocr Pract, 22, 31
- Kolb R, 2016, Curr Opin Pharmacol, 2977
- American Medical Association. 2012 Resolutions 2012. [cited 2021 Jun 30]. Available from: https://www.ama-assn.org/sites/ama-assn.org/files/corp/media-browser/public/hod/a12-resolutions_0.pdf
- Rondanelli M, 2016, Patient Prefer Adherence, 10407
- **Gorgojo-Martinez JJ, Int J Clin Pract, 73, e13399
- Ganguly R, 2018, Diabetes Res Clin Pract, 143348
Cited by
Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., de Torres-Sánchez, A., García-de-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010145 · Cited by 358
“Although reported data from trials and real-world series do not show definitive differences between GLP-1 RAs in terms of tolerability (Table 1), there are studies claiming that the tolerability profile may vary between differe t compounds [1,33,39].”
ResultJensterle, M., Rizzo, M., Haluzík, M., & Janež, A. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02153-x · Cited by 215
“No new safety signals were identified comparing participants with diabetes to non-diabetic cohorts [29].”
BackgroundPratt, E., Ma, X., Liu, R., Robins, D., Haupt, A., Coskun, T., Sloop, K. W., & Benson, C. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15184 · Cited by 62
Semaglutide in Obesity: Unmet Needs in Men
Jensterle, M., Rizzo, M., & Janež, A. (2023) · Diabetes Therapy · doi:10.1007/s13300-022-01360-7 · Cited by 36
Nikolic, D., Patti, A. M., Giglio, R. V., Chianetta, R., Castellino, G., Magán-Fernández, A., Citarrella, R., Papanas, N., Janez, A., Stoian, A. P., et al. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01217-z · Cited by 38
Metadata
- Authors
- Patel, D., & Smith, A.
- Affiliations
- Massachusetts College of Pharmacy and Health Sciences (US)
- Creighton University (US)
- Corresponding author
- Patel, Dhiren
- ORCID
- Patel, Dhiren
- Venue
- Expert Review of Clinical Pharmacology
- Publisher
- Informa UK Limited
- Published
- 2021-07-07
- Volume
- 14
- Issue
- 10
- Pages
- 1193-1204
- ISSN
- 1751-2433 (ISSN-L)
- 1751-2441
- OpenAlex
- W3182442740
- Cited by
- 16
- References
- 71
- Citations by year
- 2025: 4 · 2024: 2 · 2023: 5 · 2022: 5
- FWCI
- 0.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Expert Review of Clinical Pharmacology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk Inc
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- obesity, GLP-1 receptor agonists, anti-obesity drugs, weight management, weight loss efficacy, cardiometabolic risk factors, adverse events, treatment persistence, medication adherence, dual receptor agonist, combination therapy
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Cardiometabolic Risk Factors, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Animals, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Obesity, Weight Loss, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.